Denosumab for myeloma bone disease: ready for prime time?

Dimopoulos MA et al. Lancet Oncol. 2018 Feb 8. pii: S1470-2045(18)30075-5. doi: 10.1016/S1470-2045(18)30075-5. [Epub ahead of print].

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N et al. Lancet Oncol. 2018 Feb 8. pii: S1470-2045(18)30072-X. doi: 10.1016/S1470-2045(18)30072-X. [Epub ahead of print].

Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation.
Pandit A et al. Bone Marrow Transplant. 2018 Feb 9. doi: 10.1038/s41409-018-0112-x. [Epub ahead of print].

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
Micallef IN et al. Biol Blood Marrow Transplant. 2018 Feb 1. pii: S1083-8791(18)30056-9. doi: 10.1016/j.bbmt.2018.01.039. [Epub ahead of print].

Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report and review of the literature
Mima A et al. Clin Nephrol. 2018 Feb 2. doi: 10.5414/CN109342. [Epub ahead of print].

Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.
Leng S et al. Leuk Lymphoma. 2018 Feb 2:1-5. doi: 10.1080/10428194.2018.1429605. [Epub ahead of print].